156 related articles for article (PubMed ID: 35183375)
1. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
[TBL] [Abstract][Full Text] [Related]
2. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
3. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
[TBL] [Abstract][Full Text] [Related]
4. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
6. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
7. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
[TBL] [Abstract][Full Text] [Related]
8. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
9. Small-cell lung cancers in patients who never smoked cigarettes.
Varghese AM; Zakowski MF; Yu HA; Won HH; Riely GJ; Krug LM; Kris MG; Rekhtman N; Ladanyi M; Wang L; Berger MF; Pietanza MC
J Thorac Oncol; 2014 Jun; 9(6):892-6. PubMed ID: 24828667
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; Saigi M; Alameda D; Gomez-Mariano G; Martinez-Delgado B; Alburquerque-Bejar JJ; Carretero J; Tonda R; Esteve-Codina A; Catala I; Palmero R; Jove M; Lazaro C; Patiño-Garcia A; Gil-Bazo I; Verdura S; Teulé A; Torres-Lanzas J; Sidransky D; Reguart N; Pio R; Juan-Vidal O; Nadal E; Felip E; Montuenga LM; Sanchez-Cespedes M
Ann Oncol; 2020 Feb; 31(2):274-282. PubMed ID: 31959344
[TBL] [Abstract][Full Text] [Related]
11. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
[TBL] [Abstract][Full Text] [Related]
12. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
[TBL] [Abstract][Full Text] [Related]
13. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
[TBL] [Abstract][Full Text] [Related]
14. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
15. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon.
Chu X; Xu Y; Li Y; Zhou Y; Chu L; Yang X; Ni J; Li Y; Guo T; Zheng Z; Zheng Q; Yao Q; Li Y; Zhou X; Zhu Z
Lung Cancer; 2022 Jul; 169():22-30. PubMed ID: 35609408
[TBL] [Abstract][Full Text] [Related]
17. Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD).
Xie T; Li Y; Ying J; Cai W; Li J; Lee KY; Ricciuti B; Pacheco J; Xing P
Transl Lung Cancer Res; 2020 Dec; 9(6):2428-2439. PubMed ID: 33489804
[TBL] [Abstract][Full Text] [Related]
18. Expression of
Zhang SL; Zhang CY; Chen YQ; Li YF; Xie Z; Zhang XC; Zhou Q; Zhong WZ; Huang J; Sun H; Zheng MY; Xiao FM; Yan HH; Lu DX; Lv ZY; Wu YL; Chen HJ; Yang JJ
J Thorac Dis; 2023 Sep; 15(9):4620-4635. PubMed ID: 37868836
[TBL] [Abstract][Full Text] [Related]
19. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.
Peng Y; Zheng Z; Zewen W; Yanan L; Mingyan Z; Meili S
BMC Pulm Med; 2023 Dec; 23(1):492. PubMed ID: 38057798
[TBL] [Abstract][Full Text] [Related]
20. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
